Compile Data Set for Download or QSAR
Report error Found 270 Enz. Inhib. hit(s) with all data for entry = 11241
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.160nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.300nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.340nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 0.560nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.680nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.800nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.940nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601936(US11643416, Compound 4 | 4-((1'H-spiro[cyclohexane...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601936(US11643416, Compound 4 | 4-((1'H-spiro[cyclohexane...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601941(US11643416, Compound 23 | (S)-4-((6'-(fluoromethyl...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601941(US11643416, Compound 23 | (S)-4-((6'-(fluoromethyl...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601942(US11643416, Compound 42 | 4-((8'-methyl-7'-oxo-7',...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601942(US11643416, Compound 42 | 4-((8'-methyl-7'-oxo-7',...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601952(US11643416, Compound 54 | 2'-((4-(4-methylpiperazi...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 1nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1 [99-307](Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 1.30nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 1.40nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 1.40nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601938(US11643416, Compound 18 | (R)-4-((6'-(fluoromethyl...)
Affinity DataIC50: 1.70nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601940(US11643416, Compound 5 | 4-((1'-methyl-1'H-spiro[c...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601946(US11643416, Compound 46 | 4-((1',3'-dimethyl-1'H- ...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601946(US11643416, Compound 46 | 4-((1',3'-dimethyl-1'H- ...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601948(US11643416, Compound 50 | 6'-hydroxy-2'-((4-((4- m...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601948(US11643416, Compound 50 | 6'-hydroxy-2'-((4-((4- m...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601952(US11643416, Compound 54 | 2'-((4-(4-methylpiperazi...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601942(US11643416, Compound 42 | 4-((8'-methyl-7'-oxo-7',...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 2.20nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 2.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601938(US11643416, Compound 18 | (R)-4-((6'-(fluoromethyl...)
Affinity DataIC50: 2.70nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 2.80nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601940(US11643416, Compound 5 | 4-((1'-methyl-1'H-spiro[c...)
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601952(US11643416, Compound 54 | 2'-((4-(4-methylpiperazi...)
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601954(US11643416, Compound 59 | 8'-methyl-2'-((4-((4-met...)
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601960(US11643416, Compound 71 | 8'-methyl-2'-((4-(4- met...)
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601952(US11643416, Compound 54 | 2'-((4-(4-methylpiperazi...)
Affinity DataIC50: 3nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 3.10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 3.70nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601944(US11643416, Compound 43 | 4-((6',8'-dimethyl-7'-ox...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601944(US11643416, Compound 43 | 4-((6',8'-dimethyl-7'-ox...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601948(US11643416, Compound 50 | 6'-hydroxy-2'-((4-((4- m...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601949(US11643416, Compound 51 | 2'-((4-((4-methylpiperaz...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601951(US11643416, Compound 53 | 6'-hydroxy-2'-((4-(4- me...)
Affinity DataIC50: 4nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 270 total ) | Next | Last >>
Jump to: